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Interventional Cardiology
DS Reduces Periprocedural Myocardial Injury
Cuisset and colleagues hypothesized that microembolization during PCI can bereduced by direct stenting (DS) as opposed to stenting following balloon pre-
dilation. The index ofmicrocirculatory resistance (IMR)measures resistance to flow in
the coronarymicrocirculation; higher values indicate higher resistance, which has been
linked tomicrocirculatory embolization and inflammatory injury in the distal territory.
Fifty patients were randomized to either DS or pre-dilation. Subjects randomized to
pre-dilation had a mean IMR that was nearly twice as high as those undergoing DS.
There were also higher troponin levels in those undergoing pre-dilation. These results
suggest that DS may be superior to pre-dilation at preventing distal embolization of
microemboli. See page 1060. See figure.
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Interventional Cardiology
Double Bolus of Clopidogrel Reduces
Platelet Aggregation Compared to Single Bolus
L’Allier and colleagues compared 3 different clopidogrel loading regimens inpatients undergoing elective angiography. Subjectswere randomized to either 300
mg the day before and 75 mg the morning of, 600 mg the morning of, or 600 mg the
day before and the day of the procedure. The primary end point was the change in
adenosine diphosphate (ADP)–stimulated platelet aggregation compared to pre-
clopidogrel levels. The double 600-mg load resulted in significantly greater platelet
inhibition and a decrease in the percentage of subjects considered nonresponders.
Clopidogrel 600 mg double bolus achieves greater platelet inhibition than conven-
tional single loading doses. See page 1066. See figure.
Heart Failure
Continuous Hemodynamic Monitoring
Does Not Reduce Hospitalizations for Chronic HF
Accurately determining a patient’s volume status from symptoms is sometimesdifficult; accurate, instantaneous, continuous hemodynamic measurements may
improve titration of diuretics and prevent hospitalization. The COMPASS-HF trial
enrolled almost 300 patients with New York Heart Association functional class III to
IV heart failure (HF) who received an implantable hemodynamicmonitor, which uses
a pressure sensor in the right ventricle. In one-half of the patients, the physician was
blinded to these measurements, while in the other one-half, the measurements were
documented weekly and could be used to make medication adjustments. Those
subjects whose physicians had access to the data had a nonsignificant 21% reduction in
hospitalizations for HF. See pages 1073 and 1080.
